Showing 4681-4690 of 6036 results for "".
- ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategyhttps://modernod.com/news/proqr-announces-additional-sepofarsen-illuminate-trial-analyses-and-provides-update-on-company-strategy/2480765/ProQR Therapeutics provided an update on its sepofarsen program following a comprehensive post-hoc analysis of the data from the phase 2/3 Illuminate trial in people with CEP290-mediated Lebercongenital amaurosis 10, or LCA10, a
- Study: People with Vision Impairments up to Four Times More Likely to Suffer Mental Health Problemshttps://modernod.com/news/study-people-with-vision-impairments-up-to-four-times-more-likely-to-suffer-mental-health-problems/2480757/Research by international development organization Sightsavers, University of Ilorin, and the Kogi State Ministry of Health, in Nigeria has revealed links between vision impairment and poor mental health.
- Zeiss to Unveil Clinical Insights Supporting the Value of New Data-Driven Digital Workflow Solutions and Software Applicationshttps://modernod.com/news/zeiss-to-unveil-clinical-insights-supporting-the-value-of-new-data-driven-digital-workflow-solutions-and-software-applications/2480752/Zeiss Medical Technology will host ZEISS Innovation Day on April 7, 2022, showcasing clinical perspectives from global experts with first-hand experience integrating devices, data and software applications.
- Staar Surgical Announces First Implants of EVO Visian ICL in the UShttps://modernod.com/news/staar-surgical-announces-first-implants-of-evo-visian-icl-in-the-us/2480751/Staar Surgical announced the first implants of the EVO Visian Implantable Collamer lens (EVO ICL) in the US. The company also announced its program of meetings and presentations during the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Washington, DC, Apri
- Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocationhttps://modernod.com/news/alimera-exhibits-continued-growth-and-expansion-with-new-branding-and-office-relocation/2480750/Alimera Sciences announced that the company has launched new corporate branding and moved its global headquarters to a new, state-of-the-art facility. Alimera refreshed its corporate brand for the first time in the company’s two-decade history to better represent its current
- Shamir Group Employees Around the World are Mobilized for Humanitarian Aid for Ukrainian Refugees in Warsawhttps://modernod.com/news/shamir-group-employees-around-the-world-are-mobilized-for-humanitarian-aid-for-ukrainian-refugees-in-warsaw/2480745/Shamir is now voluntarily operating traveling laboratories for testing and fitting of eyeglasses among Ukrainian refugees, located at the Patk Expo complex in Warsaw, Poland. The mobile laboratories on wheels are equipped with advanced technology for rapid production of advanced lenses&mdash
- Amydis Appoints Robert N. Weinreb, MD, as First Chair of Scientific Advisory Boardhttps://modernod.com/news/amydis-appoints-robert-n-weinreb-md-as-first-chair-of-scientific-advisory-board/2480742/Amydis announced the appointment of clinician scientist, Robert N. Weinreb, MD, as the First Chair to the Scientific Advisory Board of the company. “Amydis is at the forefront of developing compounds that enable retinal imaging of molecula
- Researchers Generate First Complete, Gapless Sequence of a Human Genomehttps://modernod.com/news/researchers-generate-first-complete-gapless-sequence-of-a-human-genome/2480741/Scientists have published the first complete, gapless sequence of a human genome, two decades after the Human Genome Project produced the first draft human genome sequence, according to the National Institutes of Health. According to researchers, having a complete, gap-free sequen
- Outlook Therapeutics Submits Biologics License Application to the FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-submits-biologics-license-application-to-the-fda-for-ons-5010-as-a-treatment-for-wet-amd/2480738/Outlook Therapeutics announced it has submitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg), for the treatment of wet age-related macular degeneration (AMD).&nbs
- Study: Dry Eye Disease Signs and Symptoms Significantly Reduced with Ciclosporin A 0.1% Cationic Emulsionhttps://modernod.com/news/study-dry-eye-disease-signs-and-symptoms-significantly-reduced-with-ciclosporin-a-01-cationic-emulsion/2480734/Santen EMEA has announced the results of PERSPECTIVE, a real-world evidence study evaluating the long-term treatment of severe keratitis in adult dry eye disease (DED) patients. The study, which was conducted across 44 ophthalmology clinics in 5 European countries, demonstrated that ciclosporin A